• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Zoetis Could Rally Further After Some More Sideways Consolidation

Buyers will need to be patient.
By BRUCE KAMICH
Jan 14, 2021 | 08:21 AM EST
Stocks quotes in this article: ZTS

For his second "Executive Decision" segment of Wednesday night's Mad Money program, Jim Cramer spoke with Kristin Peck, CEO of Zoetis (ZTS) , the drug maker specializing in pets.

Peck explained that with the pandemic, pet adoption has risen by 15%, and with so many people spending more time with their pets, they're noticing their pets' medical needs more than ever. Zoetis has over 200 product lines across eight species. And 13 of those product lines account for over $100 million in annual sales.

Peck noted that Zoetis is also seeing strength in their livestock business and China, which saw sales up 30% as the country recovers from a swine fever epidemic. China is also seeing an increase in pet adoption.

Let's check on the charts to see if they are worth adoption. The last time we looked at ZTS it was early in the pandemic and a lot has happened since March 12 when we wrote that "It looks like Jim Cramer and I are on the same page with ZTS - let it come down before considering the long side." We gave $109 as a potential downside target but prices sank to $90 in short order.

In this updated daily bar chart of ZTS, below, we can see that prices rallied from their March nadir in fits and starts to a high in early November. Prices have traded sideways the past two-and-a-half months. ZTS just closed below the neutral 50-day moving average line which it has been crossing since October. ZTS is above the rising 200-day moving average line.

The On-Balance-Volume (OBV) line shows weakness since early November and that tells us that sellers of ZTS have been more aggressive. The Moving Average Convergence Divergence (MACD) oscillator is just slightly above the zero line.

In this weekly bar chart of ZTS, below, we can see a positive longer-term picture. Prices are in an uptrend and trading above the rising 40-week moving average line.

The weekly OBV line shows strength from the middle of 2018 but turned sideways from this October. The MACD oscillator is in a take profit sell mode but narrowing perhaps to a new buy signal.

In this daily Point and Figure chart of ZTS, below, we can see that the software is projecting a potential price target in the $194 area. Point and Figure charts do not lend themselves to any timing ideas, unfortunately.

Bottom line strategy: It looks like ZTS can move higher in 2021 as our weekly chart and the Point and Figure chart suggest. The question is when. I would anticipate some further sideways price action before renewed strength. Buyers need to be patient.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Pets | Pharmaceuticals | Mad Money | Executive Interview

More from Investing

There Are Interesting Things Happening Beneath the Surface of This Market

James "Rev Shark" DePorre
Aug 8, 2022 4:32 PM EDT

Look for more positioning on Tuesday ahead of two important economic reports.

Can Rhythm Pharmaceuticals Keep Up This Tempo?

Bruce Kamich
Aug 8, 2022 3:01 PM EDT

The stock has surged amid an analyst upgrade.

What AIG's Charts Say About the Stock Ahead of Earnings

Bruce Kamich
Aug 8, 2022 2:03 PM EDT

The stock just tested the underside of the declining 50-day moving average.

Solar Firm Sunrun Continues to Run on the Upside

Bruce Kamich
Aug 8, 2022 1:24 PM EDT

Here's what the longer-term picture looks like.

Weariness Sets in During This Bear Market Phase

Bob Lang
Aug 8, 2022 1:00 PM EDT

Sentiment is starting to turn bullish, but painted with a skeptical eye as the wall of worry is up high.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:24 AM EDT PETER TCHIR

    Jobs Report Reaction: Incredibly Strong, But Questions to Ask

    An incredibly strong July jobs report. Not only d...
  • 08:54 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The Secret to Dealing With FOMO
  • 03:51 PM EDT REAL MONEY

    AMD Second-Quarter Earnings Live Blog

    Real Money's Eric Jhonsa covers 's second-quarte...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login